Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01299480 | A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years | PHASE2 | COMPLETED | 1,714 | — | — | Mar 3, 2011 | Sep 18, 2012 | Oct 27, 2022 | 63 | Czechia, Denmark +5 |
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | rLP2086 vaccine at visits 1, 2 and 5, saline at visit 3 |
| Group 2 | EXPERIMENTAL | rLP2086 vaccine at visits 1, 3, and 5, saline at visit 2 |
| Group 3 | EXPERIMENTAL | rLP2086 vaccine at visits 1, and 5, saline at visits 2 and 3 |
| Group 4 | EXPERIMENTAL | rLP2086 at visits 1 and 3, saline at visits 2 and 5 |
| Group 5 | EXPERIMENTAL | rLP2086 at visits 3 and 5, saline at visits 1 and 2 |
| Name | Type | Description |
|---|---|---|
| Vaccine | BIOLOGICAL | rLP2086 vaccine at visits 1, 2 and 5, saline at visit 3 |
Inclusion Criteria: * Evidence of a personally signed and dated informed consent document indicating that the parent/legally acceptable representative and/or subject has been informed of all pertinent aspects of the study. * Parent/legally acceptable representative and/or subjects who are willing a...